Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Monovalent Influenza Vaccine A (H5N8) in Adults and Older Adults
NCT06842173Phase 2Recruiting
- Sponsor
- Instituto Butantan
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza vaccine A (H5N8) in Avian Influenza (AI) (3 arms), sponsored by Instituto Butantan. Primary endpoints: Percentage of participants with solicited and unsolicited adverse events and adverse reactions, Seroconversion rate post second vaccination and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
influenza vaccine A (H5N8)
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT06842173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842173.